IN PARTNERSHIP WITH CSI

FIRST ANNOUNCEMENT

Apr.14-16, 2017

Hangzhou, China

SPONSORSecond A�liated Hospital, Zhejiang University School of Medicine

CO-SPONSORCSI (Catheter Interventions in Congenital, Structural and Valvular Heart Disease)

WELCOMING REMARKS

Dear colleagues and friends,

Incidence of valvular heart diseases keeps increasing along with the

aging trend of the world, and makes it a serious threat to human health.

As the evidence accumulates, transcatheter valvular replacement or

repair emerged as an alternative for traditional cardiac surgery,

especially in the �eld of transcatheter aortic valve replacement (TAVR).

However, development of transcatheter valvular treatment in China is

still at the initial status. There is an urgent call for systemic training for

Chinese interventional cardiologists and their heart valve teams.

To improve transcatheter valvular treatment in China and international

collaboration in the �eld, the third China Valve (Hangzhou) congress

will be held on 14th to 16th April 2017. This year, we will continuously

work with the support of CSI to provide a broader global vision, an

improved training course and a deeper communicative platform. The

program will include step by step learning from recorded cases, live

cases, hands-on sessions, imaging training, up-to-date clinical trials

and debates on hot spots, etc.

Hangzhou is an ancient, yet highly civilized city rich in both historical

sites and natural landscapes, such as the West Lake and Grand Canal.

The city is also an international metropolis where the G20 summit held

in September 2016. You will have the opportunity to enjoy the wonder-

ful scenery after scienti�c activities.

Welcome to Hangzhou!

Course Chairman: Junbo Ge

Course Directors: Jian’an Wang Horst Sievert

ORGANIZATION

Honorable Chairmen

Course Chairman

Course Directors

Runlin GAO

(Beijing, China)

Yong HUO

(Beijing, China)

Junbo GE

(Shanghai, China)

Jian’an WANG

(Zhejiang, China)

Horst SIEVERT

(Course director of CSI, Germany)

ORGANIZATION

International Faculties (In Alphabetic Order)

Anthony DEMARIA (UCSD Medical Center, USA)

Khalil FATTOUCH (Maria Eleonora Hospital, Italy)

Ulrich GERCKENS (Gemeinschaftskrankenhaus, Bonn, Germany)

Robert GOOLEY (MonashHEART, Australia) Eberhard GRUBE (Siegburg Heart Center, Germany)

Kentaro HAYASHIDA (Keio University, Japan) Dongming HOU (USA)

Hasan JILAIHAWI (NYU Langone Medical Center, USA)

Patrizio LANCELLOTTI (University of Liège, Belgium)

Thomas MODINE (Lille University Hospital, France)

Duk-Woo PARK (ASAN Medical Center，Korea)

Advisory Committee (In Alphabetic Order)

Daniel Tai-Leung CHAN (Queen Mary Hospital, Hong Kong) Mao CHEN (Sichuan, China)

Yundai CHEN (Beijing, China) Yaling HAN (Shenyang, China)

Dejia HUANG (Sichuan, China) Xiangqing KONG (Jiangsu, China)

Michael Kang-yin LEE (Queen Elizabeth Hospital, Hongkong) Simon Cheung-Chi LAM (Queen Mary Hospital, Hong Kong)

Yat-Yin LAM(Hongkong Society of Congenital and Structural Heart Disease) Yongjian WU (Beijing, China)

Bo XU (Beijing, China) Yuejing YANG (Beijing, China)

Wei-Hsian YIN (Cheng-Hsin General Hospital, Taiwan) Ruiyan ZHANG (Shanghai, China)

Daxin ZHOU (Shanghai, China)

Scienti�c Committee (In Alphabetic Order)

Jiyan CHEN (Guangdong, China) Shaoliang CHEN (Jiangsu, China)

Xiaoshu CHEN (Jiangxi, China) Yuan FENG (Sichuan, China)

Yingqiang GUO (Sichuan,China) Ben HE (Shanghai, China) Guoqing LI (Xinjiang, China) Xianhe LIN (Anhui, China) Genshan MA (Jiangsu, China) Yitong MA (Xinjiang, China) Yongwen QIN(Shanghai, China) Xi SU (Hubei, China) Yong SUN (Zhejiang, China) Ling TAO (Shanxi, China) Hongju WANG (Anhui, China) Yan WANG (Fujian, China) Qiang WU (Guizhou, China) Yanqing WU (Jiangxi, China) Meixiang XIANG (Zhejiang, China) Biao XU (Jiangsu, China) Bo YU (Heilongjiang, China) Zaixin YU (Hunan, China) Zuyi YUAN (Shanxi, China) Heng ZHANG (Anhui, China) Xianxian ZHAO (Shanghai, China)

Secretariats

Jun JIANG (Zhejiang, China) Xianbao LIU (Zhejiang, China)

PROGRAM DRAFT

April 14 Friday

Main ArenaSession 1: 13:30-15:00　Learning from recorded TAVR case step by step

Clinical evaluation

Echocardiographic evaluation

CT analysis

Heart valve team discussion

(cardiologist, surgeon, anesthesiologist, radiologist, nurse etc.)

Recorded TAVR case step by step

Session 2: 15:30-16:30　Optimising TAVR outcomes

Clinical situation: where are the limits

How to evaluate and get vascular access safely

How to choose correct THV and valve size

Double S curve guided deployment

Session 3: 17:00-18:00　Making TAVR simple?

Local or general anesthesia?

TTE or TEE guidance?

Hybrid or ordinary catheter room?

Will TAVR be performed as PCI in the future?

Heart valve team will be changed in the future?

Room 3

Hands on training

How to perform transcatheter self-expanding aortic valve with VENUS A

How to perform transcatheter mechanical-expanding Lotus valve

April 15 Saturday

Main ArenaSession 4 08:00-09:00　Moving farward to lower risk patients

What’s the real di�erence between high risk and lower risk patients

The limitations of surgery in lower risk patient-perspectives from interventionalist

The limitations of TAVR in lower risk patient-perspectives from surgeon

Latest evidence and limitations

PROGRAM DRAFT

April 15 Saturday

Main Arena09:00-09:30　Opening ceremony

Session 5 09:30-10:30　Dialogues of TAVR between China and the world

Current status

Bicuspid aortic valve

Severe calci�cation and thickened lea�ets

Home-made devices and new generation devices

Perspectives from cardiologists and surgeons

Session 6 10:30-12:30　Live cases

Session 7 13:30-15:00　Long term outcomes and bioprothetic valve durability

Controversies of TAVR bioprostheses deterioration

Why might TAVR bioprotheses fail

Lessons from surgical experience

Subclinical thrombosis and lea�et thickening

TAV in TAV: current status and future

TAVR for younger patients: my thinking

Session 8 15:00-17:00　Live cases

Session 9 17:00-18:00　Percutaneous mitral and tricuspid valves intervention

Anatomic challenges

Update of transcatheter mitral valve replacement or repair

Current status of percutaneous tricuspid valve intervention

Experience from China

Room 2

Session1 13:30-15:30　TAVR for bicuspid aortic valve

Anatomic characteristics and procedural considerations

What guideline say and up-to-date outcomes of clinical studies

Advantages and disadvantages of di�erent transcatheter heart valves

Sizing strategy and outcomes - experience from China

Cases

Session2 16:00-18:00　International challenging TAVR cases

PROGRAM DRAFT

Room 3 Hands on training

How to perform transcatheter self-expanding aortic valve with VENUS A

How to perform transcatheter mechanical-expanding Lotus valve

April 16 Sunday

Main ArenaSession 10 08:00-09:00　How to design TAVR clinical studies and get published

Session 11 09:00-10:30　Management of complications-1

Case 1 PVL

How to prevent and treat PVL

Case 2 vascular complication

How to prevent and treat vascular complications

Case 3 conduction disturbance

Predictors of conduction disturbance and how to minimize PPM

Session 12 10:30-12:00　Management of complications-2

Case 4 stroke

Predictors of stroke and prevention

Case 5 Coronary obstruction

How to prevent and treat coronary obstructions

Case 6 annulus rupture or myocardial perforation

How to prevent and treat annulus rupture or myocardial perforation

Room 3

Hands on training

How to perform transcatheter self-expanding aortic valve with VENUS A

How to perform transcatheter mechanical-expanding Lotus valve

CONFERENCE INFORMATION

Conference Venue　The Dragon Hotel, Hangzhou, China

Address 120 Shuguang Road, Hangzhou, China 310007

Hotel Tel +86 400 600 0676

Website　www.china-valve.org.cn

Pre-registration on line　up to 31st March, 2017

Pre-registration Fee 　¥800

Registration on the spot　14th to 15th April, 2017

Registration Fee　¥1000

Contacts　Qiyuan Xu　Yan Lin

Tel　+86 158 6904 9557 　+86 187 6811 5530

Email　CVH2017@ china-valve.org.cn